Bio-Quant’s drug development unit focuses on the development and commercialization of innovative therapeutic products to address the unmet medical needs of patients including life-threatening orphan diseases in the areas of cancer and immunology. The company differentiates itself from the competition by developing natural products that meet the FDA’s botanical drug guidelines.

In order to secure a steady and proprietary source of compounds, the company has generated a proprietary library of close to 50,000 compounds that we currently use in our drug screening platform. This unique approach provides us with the following advantages over the competition:

• Documented human exposure data meeting the FDA botanical drug guideline
• Non-cytotoxic compounds eliminated by pre-screening against human cells/tissues
• Rapid identification and screening in human cell based disease models
• Orphan cancer treatments are expected to qualify for fast track / orphan drug status to allow an expedited review by the FDA
• Natural products with documented human safety data are permitted to go directly into Phase II or III trials